IGC PHARMA INC (IGC)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$0.30-0.17%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · IGC
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 86.5% |
| Our one-year growth estimate | diamond | -19.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 105.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 399 industry peers · Company calendar date is not available
IGC — capital allocation — Unregistered Sales of Equity Securities
Dated 2026-07-06
Unregistered Sales of Equity Securities. The information set forth in
Why it matters: Improving revenue is essential for IGC to support its operations and trials.
Worry ifRevenue shows a quarter-over-quarter increase from the current low of $265K.
Less concerning ifRevenue continues to decline or remains stagnant below $265K.
Why it matters: Regulatory updates can change when IGC-AD1 gets approved. Good news may boost investor trust.
Supportive ifAny good feedback or guidance from the FDA about IGC-AD1 will be announced.
Worry ifBad feedback or delays from the FDA about approval will be announced.
Why it matters: Big losses mean serious money issues. This can make investors less confident.
Worry ifOperating losses are more than -$3 million in Q3 2026.
Less concerning ifOperating losses improve to less than -$3 million in Q3 2026.
Why it matters: Higher capital obligations can mean financial trouble. This may hurt stock performance.
Worry ifNew capital obligations are over $1 million in Q3 2026.
Less concerning ifCapital obligations stay the same or go down in Q3 2026.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$141 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $479 loss on $10,000 · 4.8% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,466 loss on $10,000 · 44.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: An improvement here would show progress in reducing losses. It could boost investor sentiment.
Supportive ifNet income reported better than -$1.8 million.
Worry ifNet income reported worse than -$1.8 million.
Why it matters: New financing can help the company and support its work. This may help investors.
Supportive ifA new loan or financing deal over $1 million is announced.
Worry ifNo new financing deals are announced in the next quarter.
Why it matters: A drop below this level shows ongoing struggles in revenue generation. It signals that the company's efforts to improve revenue are not working.
Worry ifQ2 revenue reported below $191,000.
Less concerning ifQ2 revenue reported above $191,000.
Why it matters: Ongoing financing is crucial for IGC's operations. Changes could impact cash flow and stability.
Worry ifIGC gets a new financing deal. This helps make cash flow more stable.
Less concerning ifIGC announces more debt or bad financing terms.
Why it matters: Revenue trends show the company's financial health and market acceptance. Falling revenue could mean bigger problems.
Worry ifRevenue is stabilizing or growing after recent drops.
Less concerning ifRevenue keeps going down. This shows ongoing problems with market acceptance.
Why it matters: Revenue trends will show if the company is improving its financial health. This is critical for investor confidence.
Watch forRevenue shows a big increase from the last quarter.
Also watch forRevenue goes down more or stays the same from the last quarter.
Why it matters: Completing enrollment is a key step for the trial. It shows progress in testing IGC-AD1 for Alzheimer's agitation.
Supportive ifManagement says enrollment is done for the CALMA trial.
Worry ifEnrollment is still not complete past the expected time.
Why it matters: Topline results will show how well IGC-AD1 works. Good results could raise the company's value.
Supportive ifTopline results show a big drop in agitation from the baseline.
Worry ifTopline results show no big change in agitation.